drugset / Trial / NCT00485550

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy

NCT00485550

Phase 3 Completed 14 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of atomoxetine alone versus atomoxetine plus low-dose, sustained-release MPH in children with treatment-resistant ADHD.

Timeline

Start
2004-01
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified
Subject Methylphenidate Small molecule